44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Immune Disorders & Therapy

Sign up for email alert when new content gets added: Sign up

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study

Author(s): Miguel García-Grimshaw, Santa Elizabeth, Ceballos-Liceaga, Gustavo Reyes-Terán, Antonio Arauz and Sergio Iván Valdés-Ferrer

Vaccines are the single most effective mechanism to control the ongoing COVID-19 global crisis. However, in part due to their relatively recent incorporation into the preventive armamentarium, hesitancy towards mRNA-based COVID-19 vaccines is high despite evidence of efficiency. Hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI). We found an overall frequency of 3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the arms (61%) and face/neck region (36.2%) were the most commonly affected sites. The control group had significantly higher rates of reactogenicity-associated symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54; 95% CI 0.40–0.72; p p<0.001). This is the first study describing the topography and associated factors for developing NSSS among BNT162b2 recipients. The benign nature of these symptoms may help dissipate hesitation towards this vaccine.

Google Scholar citation report
Citations : 2

Journal of Immune Disorders & Therapy received 2 citations as per Google Scholar report